

## **OPEN ACCESS**

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

\*CORRESPONDENCE
Frontiers Production Office

☑ production.office@frontiersin.org

RECEIVED 29 March 2024 ACCEPTED 29 March 2024 PUBLISHED 10 April 2024

### CITATION

Frontiers Production Office (2024) Erratum: Effect of the ROCK inhibitor fasudil on the brain proteomic profile in the tau transgenic mouse model of Alzheimer's disease. *Front. Aging Neurosci.* 16:1409164. doi: 10.3389/fnaqi.2024.1409164

## COPYRIGHT

© 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Erratum: Effect of the ROCK inhibitor fasudil on the brain proteomic profile in the tau transgenic mouse model of Alzheimer's disease

# Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

Alzheimer's disease, fasudil, PS19, P301S, tau, proteomic

# An Erratum on

Effect of the ROCK inhibitor fasudil on the brain proteomic profile in the tau transgenic mouse model of Alzheimer's disease


Collu, R., Yin, Z., Giunti, E., Daley, S., Chen, M., Morin, P., Killick, R., Wong, S. T. C., and Xia, W. (2024). Front. Aging Neurosci. 16:1323563. doi: 10.3389/fnagi.2024.1323563

Due to a production error, there was a mistake in Figure 1 as published. Figure 1B is supposed to be Figure 1C and Figure 1C is supposed to be Figure 1B.

The correct figure appears below:

The publisher apologizes for this mistake. The original article has been updated.

Frontiers Production Office 10.3389/fnagi.2024.1409164



PS19 transgenic mice brain proteomic profile. (A) Graphical representation of the experimental timeline of this study including groups, drug treatment, biochemical and statistical analysis performed. (B) Levels of total tau (Tau) and phosphorylated tau (pTau)-181, -202, -231, and -396 in the brain of PS19 transgenic mice as compared to non-carrier (NC) mice measured with MSD ELISA. (C) Gene ontology enrichment analysis of differentially expressed proteins in the brain of PS19 as compared to NC mice. Significantly enriched biological process, cellular components, and molecular functions are represented and were obtained with DAVID. (D) KEGG and Reactome pathway enrichment analysis of differentially expressed proteins in the brain of PS19 as compared to NC mice. Bubble plot represents the top significant pathways.